Table 2.
Univariate and multivariate analysis of PFS among included patients
| Parameters | No. | Events | Univariate analysis | Multivariate analysis | ||||
|---|---|---|---|---|---|---|---|---|
| Median PFS (95% CI) | Log‐rank p value | HR (95% CI) | p value | HR (95% CI) | p value | |||
| Age, years | — | — | ||||||
| <65 | 26 | 16 | 12.1 (8.0–16.2) | .048 | 1 | .061 | ||
| ≥65 | 10 | 3 | 18.5 (12.7–24.3) | 0.30 (0.85–1.06) | ||||
| Menopausal status | — | — | ||||||
| Premenopausal | 8 | 5 | 10.3 (3.9–16.7) | .446 | 1 | .447 | ||
| Postmenopausal | 28 | 14 | 14.6 (9.7–19.5) | 0.67 (0.24–1.90) | ||||
| Disease‐free interval, years | — | — | ||||||
| ≤5 | 7 | 6 | 7.2 (3.4–11.0) | .096 | 1 | .109 | ||
| >5 | 18 | 7 | 18.5 (12.5–24.5) | 0.38 (0.12–1.24) | ||||
| Visceral disease | — | — | ||||||
| No | 21 | 10 | 13.1 (11.5–14.7) | .716 | 1 | .717 | ||
| Yes | 15 | 9 | 14.6 (3.3–25.9) | 0.84 (0.32–2.21) | ||||
| De novo metastatic disease | — | — | ||||||
| No | 25 | 13 | 14.6 (9.5–19.7) | .842 | 1 | .843 | ||
| Yes | 11 | 6 | 12.4 (7.6–17.2) | 1.11 (0.41–3.00) | ||||
| Prior palliative chemotherapy | — | — | ||||||
| No | 31 | 14 | 14.6 (10.9–18.3) | .467 |
1 1.51 (0.49–4.66) |
.470 | ||
| Yes | 5 | 5 | 12.4 (2.3–22.5) | |||||
| Number of prior lines of palliative ET | — | — | ||||||
| 0 | 27 | 11 | 18.5 (12.3–24.7) | .118 | 1 | .127 | ||
| ≥1 | 9 | 8 | 12.1 (7.7–16.5) | 2.12 (0.81–5.55) | ||||
| ΔSUVmax | ||||||||
| <38.0% | 7 | 7 | 3.5 (3.0–4.0) | .003 | 1 | .006 | 1 | .006 |
| ≥38.0% | 29 | 12 | 28.0 (not reached) | 0.26 (0.10–0.68) | 0.26 (0.10–0.68) | |||
| Baseline SUVmax | ||||||||
| <3.1 | 9 | 6 | 10.3 (8.0–12.6) | .317 | 1 | .323 | — | — |
| ≥3.1 | 27 | 13 | 14.6 (10.8–18.4) | 0.61 (0.23–1.63) | ||||
| Scan 2 SUVmax | ||||||||
| ≤2.1 | 19 | 9 | 14.6 (7.4–21.8) | .342 | 1 | .347 | — | — |
| >2.1 | 17 | 10 | 12.4 (11.3–13.5) | 1.57 (0.62–3.98) | ||||
| With negative 18F‐FES lesions | ||||||||
| No | 26 | 11 | 14.6 (8.4–20.8) | .081 | 1 | .089 | — | — |
| Yes | 10 | 8 | 7.2 (3.0–11.4) | 2.29 (0.88–5.93) | ||||
Bold type indicates significance.
Abbreviations: —, no data; ΔSUVmax, median change in maximum standard uptake value CI, confidence interval; ET, endocrine therapy; FES, fluoroestradiol; HR, hazard ratio; MBC, metastatic breast cancer; PFS, progression‐free survival; SUVmax, maximum standard uptake value.